Amarin Corp Plc (AMRN)

[Jasbg]

Learning all the time here. And a major thing is' - that I had no idea the size of these generic company's.

And next thing you learn - these companies 'are build' around these legal cases - fighting Brand names who paid for research and development of the drugs.

Truth 2020 are - we are talking about 'blod hounds' in the Bio Business that are 'Very - Very succesful - in what they do'.
--------------------------------

Look at the Size of Hikma and Reddy (eg. number of employees) these are big companies - we are up against (data from 2018):

Dr Reddy:

Generic Segment Revenue: $1.77B Total Employees: ~21,966

Founded Year: 1984 Headquarter: Telangana, India

Market Cap: ~$6.32B Stock Exchange: NSE

Dr Reddy’s Laborataries is a global pharmaceutical company with three divided segments Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products. The company focusses on GI, cardiovascular, diabetology, oncology, pain management and anti-infective. In 2018, the company filed 20 ANDAs with the US FDA along with 110 generic filings pending approval, comprising 107 ANDAs and 3 NDA filed under the Section 505(b)(2) route.
---------------------------------------

Hikma:

Generic Segment Revenue: $2.01B Total Employees: ~8,400

Founded Year: 1978 Headquarter: London, United Kingdom

Market Cap: ~$5.80B Stock Exchange: LSE

Hikma is a global pharmaceutical firm focusing on the development and marketing of generics, branded products and injectables anti-infectives, cardiovascular, CNS, diabetes including oncology, pain management and respiratory. The company’s generic segmnet has demonstrated 13% increment to 2017. The company launched 90+ products in 2018. Additionally, in 2018 the company received the US FDA’s approval for Ritonavir Tablets USP, 100 mg used in combination with antiretroviral agents for treatment of human immunodeficiency virus (HIV-1) infection.

Jasbg

NB: One of Bill Gates forces were - 'know your competition' - this surely is important in Bio Business also.